Terminated PHASE2/PHASE3 INTERVENTIONAL NCT00057382

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Sponsor: Tularik

Interventions T138067 intravenous doxorubicin intravenous

Updated 6 times since 2017 Last updated: Jun 23, 2005 Started: Mar 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Tularik

Non-Hodgkin's Lymphoma · Phase PHASE2 · Mar 2003

More terminations from Tularik

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

A PHASE2/PHASE3 clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Tularik and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tularik

Data source: Tularik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Barnaul, Russia , Beijing, China , Belo Horizonte, Brazil , Birmingham, United States , Cambridge, United Kingdom , Chelyabinsk, Russia , Chongqing, China , Dallas, United States , Dnipro, Ukraine and 51 more locations